Stockscreener 앱 받기
22.03
1.94%
0.42
전일 마감가:
$21.61
열려 있는:
$21.89
하루 거래량:
915.50K
Relative Volume:
0.67
시가총액:
$3.73B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
122.39
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-6.49%
1개월 성능:
-16.74%
6개월 성능:
-12.34%
1년 성능:
+11.43%
1일 변동 폭
$21.79
$22.19
1주일 범위
$21.51
$23.54
52주 변동 폭
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.03 | 3.66B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - Barchart.com
Glioblastoma Pipeline 2025: Therapies Under Investigation, - openPR.com
Can ACADIA Pharmaceuticals Inc. stock sustain institutional interestCEO Change & Weekly High Potential Alerts - mfd.ru
Understanding Momentum Shifts in (ACAD) - Stock Traders Daily
ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch - TipRanks
Can ACADIA Pharmaceuticals Inc. sustain its profitabilityLayoff News & Verified Momentum Watchlists - mfd.ru
Candriam S.C.A. Buys New Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 6,950 Shares of Stock - MarketBeat
ACADIA Pharmaceuticals Inc. (ACAD): Investor Outlook Reveals 34% Upside Potential Amid Robust CNS Pipeline - DirectorsTalk Interviews
ACADIA Pharmaceuticals: Biotech Optimism Meets Volatile Reality After A Sharp Pullback - AD HOC NEWS
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shares Lagging The Market But So Is The Business - 富途牛牛
ACAD: Oppenheimer Raises Price Target to $23, Maintains Rating | - GuruFocus
Oppenheimer Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Acadia Pharmaceuticals stock price target raised to $23 from $21 at Oppenheimer - Investing.com Canada
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug EndMonth: How do insiders feel about ACADIA Pharmaceuticals IncEarnings Risk Report & Capital Protection Trading Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals (ACAD) Is Down 5.5% After EMA Trend Vote Goes Against Daybue In Europe - Sahm
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
European regulators unlikely to recommend approval of Daybue - Rett Syndrome News
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Acadia Pharmaceuticals Shares Drop After Phase 3 PWS Trial Misses Primary Goal - MSN
A Glimpse Into The Expert Outlook On ACADIA Pharmaceuticals Through 11 Analysts - Benzinga
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $31 - 富途牛牛
EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug - Benzinga
ACAD Maintains Outperform Rating Despite Lowered Price Target | - GuruFocus
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
Acadia Pharmaceuticals stock price target lowered to $31 at RBC Capital - Investing.com Canada
EU Not The Land Of Plenty For Acadia After Rett Therapy Snub - Citeline News & Insights
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
ACADIA Pharmaceuticals (ACAD) Analyst Rating Reaffirmed by Citiz - GuruFocus
Citizens Jmp Reiterates Market Outperform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
ACAD: HC Wainwright & Co. Reiterates Buy Rating with $37 Target - GuruFocus
Acadia Pharmaceuticals stock faces EMA hurdle for Rett syndrome drug By Investing.com - Investing.com Canada
Acadia Pharmaceuticals stock faces setback as CHMP signals negative vote By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - Eastern Progress
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union - BioSpace
The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval - Yahoo Finance
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Strong One Year Share Price Gain? - Sahm
CHMP signals negative stance on Acadia's Rett syndrome drug ahead of opinion - FirstWord Pharma
Acadia Faces EMA Setback On Rett Drug As Regulatory Test Looms - Yahoo Finance
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug By Investing.com - Investing.com South Africa
Is It Too Late To Consider ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Rebound? - Yahoo Finance
Acadia faces setback in EU approval for Rett syndrome treatment By Investing.com - Investing.com India
Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome - TipRanks
Acadia Pharmaceuticals Provides Update on Regulatory Submission f - The National Law Review
Acadia Pharma down after negative EU trend vote on neurological disorder drug - TradingView
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug - Investing.com
Acadia Pharmaceuticals Submits Marketing Authorization Application for Trofinetide to European Medicines Agency - geneonline.com
Why Did ACAD Stock Slump 8% After Hours Today? - Stocktwits
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):